Merus MRUS 深 沪
等待开盘 05-20 09:30:00 美东时间
90.00
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 90.00
- 总市值 68.21亿
- 52周最高 97.14
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 33.19
- 委 比 0.00%
- 总股本 7578.44万
- 历史最高 97.14
- 量 比 0
- 振 幅 0.00%
- 历史最低 7.255
- 每 手 1
- 风险率 18.15%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D.
LeonaBio, Inc. has expanded its Board of Directors with the addition of Fred Callori, Natalie Holles, and Peter B. Silverman, effective May 5, 2026, while John Fluke Jr. retired on May 4, 2026. The new members bring extensive experience in oncology and neurology drug development, corporate strategy, operational execution, and capital markets. Their expertise aligns with LeonaBio's focus on advancing its clinical pipeline for diseases with high un...
05-07 13:20
Halozyme 2025 revenue up 38%, Q4 EPS misses estimates
Halozyme 2025 revenue up 38%, Q4 EPS misses estimates Overview Biopharmaceutical firm's 2025 revenue rose 38% to $1.4 bln, driven by ENHANZE growth Q4 adjusted EPS missed analyst expectations Company completed acquisitions of Elektrofi and Surf Bio, expanding technology portfolio Outlook Halozyme re
02-18 05:09
Merus Completes Genmab Acquisition and Delists From Nasdaq
Merus ( ($MRUS) ) has provided an update. On September 29, 2025, Merus N.V. ent...
2025-12-30 22:17
Genmab ends development of late-stage oncology asset acasunlimab
Genmab (GMAB) has decided to discontinue development of acasunlimab, which was in phase 3 for non-small cell lung cancer, to focus on other assets in its pipeline as well as its marketed product, Epki...
2025-12-29 23:07
健玛生物终止一款在研抗癌疗法研发
丹麦药企健玛生物（Genmab）周一宣布，将终止一款已进入后期临床试验的在研抗体抗癌疗法的研发工作。 2024 年，百欧恩泰（BioNTech）决定不再...
2025-12-29 22:11
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Dec. 16, 2025 /PRNewswire/ -- USANewsGroup.com News Commentary – Gastrointestinal cancers that once resisted checkpoint inhibitors ...
2025-12-17 02:17
Merus Acquired by Genmab, Leadership Changes Announced
An announcement from Merus ( ($MRUS) ) is now available. On December 11, 2025, ...
2025-12-12 21:18
Major Victory For Genmab As Epkinly Receives FDA Approval For Type Of Pretreated Blood Cancer
Genmab's Epkinly receives traditional FDA approval for relapsed or refractory follicular lymphoma in combination and monotherapy. Clinical trial data show superior results.
2025-11-19 01:58
BRIEF-Merus And Halozyme enter global collaboration and license agreement to develop subcutaneous formulation Of Petosemtamab
Nov 17 (Reuters) - Merus NV 2GH.F: MERUS AND HALOZYME ENTER GLOBAL COLLABORATION AND LICENSE AGREEMENT TO DEVELOP SUBCUTANEOUS FORMULATION OF PETOSEMTAMAB MERUS NV - TO MAKE UPFRONT AND MILESTONE PAYM...
2025-11-17 20:19
Merus N.V. Shareholders to Vote on Genmab Acquisition Offer
New activity is brewing for Merus ( ($MRUS) ). The company has submitted a Form...
2025-11-12 21:40
